Clinical trial
A Phase II Study of Tergenpumatucel-L (HyperAcute Lung) Cancer Vaccine in Subjects With Advanced Non-Small Cell Lung Cancer Who Responded to First Line Platinum-Doublet Treatment
NCT00420732 is registered in ClinicalTrials.gov with NewLink Genetics Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study of Tergenpumatucel-L (HyperAcute Lung) Cancer Vaccine in Subjects With Advanced Non-Small Cell Lung Cancer Who Responded to First Line Platinum-Doublet Treatment
- Lead sponsor
- NewLink Genetics Corporation
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- January 31, 2007
- Completion date
- December 31, 2014
- Enrollment
- 6 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.